Carine Masquefa

List of Publications by Year
in descending order

31 papers	618 citations	623574 14 h-index	580701 25 g-index
31 all docs	31 docs citations	31 times ranked	673 citing authors

#	Article	IF	Citations
1	EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML. International Journal of Molecular Sciences, 2022, 23, 3421.	1.8	7
2	Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action. European Journal of Medicinal Chemistry, 2021, 212, 113031.	2.6	11
3	Fused Azolo-Quinoxalines: Candidates for Medicinal Chemistry. A Review of their Biological Applications. Current Medicinal Chemistry, 2021, 28, 712-749.	1.2	1
4	Imiquimod Targets Toxoplasmosis Through Modulating Host Toll-Like Receptor-MyD88 Signaling. Frontiers in Immunology, 2021, 12, 629917.	2.2	12
5	Substantial Cellular Penetration of Fluorescent Imidazoquinoxalines. Journal of Fluorescence, 2020, 30, 1499-1512.	1.3	1
6	Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. European Journal of Medicinal Chemistry, 2020, 193, 112238.	2.6	77
7	Methylation of imidazopyrazine, imidazoquinoxaline, and pyrazoloquinoxaline through Suzukiâ€“Miyaura cross coupling. Chemistry of Heterocyclic Compounds, 2018, 54, 183-187.	0.6	3
8	Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 369-379.	1.4	2
9	Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells. Molecules, 2018, 23, 2987.	1.7	12
10	EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica. PLoS Neglected Tropical Diseases, 2018, 12, e0006854.	1.3	24
11	Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia. Cancer, 2017, 123, 1662-1673.	2.0	24
12	Fluorescence Study of Imidazoquinoxalines. Journal of Fluorescence, 2017, 27, 1607-1611.	1.3	5
13	Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline andÂPyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors. European Journal of Medicinal Chemistry, 2017, 138, 909-919.	2.6	22
14	Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. PLoS ONE, 2017, 12, e0182022.	1.1	20
15	Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503. International Journal of Pharmaceutical Investigation, 2017, 7, 155.	0.2	5
16	New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structureâ€“activity relationships. Bioorganic and Medicinal Chemistry, 2016, 24, 2433-2440.	1.4	32
17	New IKK inhibitors: Synthesis of new imidazo[1,2-a]quinoxaline derivatives using microwave assistance and biological evaluation as IKK inhibitors. European Journal of Medicinal Chemistry, 2016, 115, 268-274.	2.6	16
18	Synthesis of Some Imidazo[1,2-a]pyrazine Derivatives and Evaluation of Their Antinociceptive Activity. Clinical and Experimental Health Sciences, 2016, 6, 9-13.	0.1	0

#	Article	IF	Citations
19	EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. Anti-Cancer Drugs, 2014, 25, 624-632.	0.7	15
20	Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatographyâ€“tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 429-440.	1.4	10
21	Characterization of a New Anticancer Agent, EAPB0203, and Its Main Metabolites: Nuclear Magnetic Resonance and Liquid Chromatographyâ€“Mass Spectrometry Studies. Analytical Chemistry, 2012, 84, 9865-9872.	3.2	12
22	Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. European Journal of Pharmaceutical Sciences, 2010, 39, 23-29.	1.9	24
23	Metabolism and Pharmacokinetics of EAPB0203 and EAPB0503, Two Imidazoquinoxaline Compounds Previously Shown to Have Antitumoral Activity on Melanoma and T-Lymphomas. Drug Metabolism and Disposition, 2010, 38, 1836-1847.	1.7	14
24	Quantitation of imidazo[1,2â€‹a]quinoxaline derivatives in human and rat plasma using LC/ESIâ€MS. Journal of Separation Science, 2009, 32, 1363-1373.	1.3	11
25	New imidazo[1,2-a]quinoxaline derivatives: Synthesis and in vitro activity against human melanoma. European Journal of Medicinal Chemistry, 2009, 44, 3406-3411.	2.6	45
26	In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 6601-6610.	1.4	104
27	EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-Iâ€associated adult T-cell leukemia/lymphoma. Blood, 2008, 111, 3770-3777.	0.6	36
28	Design and synthesis of novel imidazo[1,2- a]quinoxalines as PDE4 inhibitors. Bioorganic and Medicinal Chemistry, 2004, 12, 1129-1139.	1.4	30
29	Imidazo[1,2-a]quinoxalines: synthesis and cyclic nucleotide phosphodiesterase inhibitory activity. European Journal of Medicinal Chemistry, 2001, 36, 255-264.	2.6	26
30	1-[1-(2-Benzo[b]thiopheneyl)cyclohexyl]piperidine hydrochloride (BTCP) yields two active primary metabolites in vivo. European Journal of Pharmaceutical Sciences, 2000, 9, 345-354.	1.9	8
31	1-[1-(2-Benzo[b]thiopheneyl)cyclohexyl]piperidine Hydrochloride (BTCP) Yields Two Active Primary Metabolites in Vitro:Â Synthesis, Identification from Rat Liver Microsome Extracts, and Affinity for the Neuronal Dopamine Transporter. Journal of Medicinal Chemistry, 1997, 40, 4019-4025.	2.9	9